Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer, Novartis US, responsible for the expansion of medicines across oncology, immunology, neurology, and cardiovascular, ...

One of the secrets to living a longer, better life is beating in our chests. An estimated 80% of cardiovascular disease (CVD) can be prevented with lifestyle changes and available tools, yet it ...

About Novartis in Cardiovascular Disease At Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We’re proud ...

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only.

Career Search Explore opportunities with Novartis below. Notice to applicants for US job openings. Learn More Be aware of fake job advertisements and job offers. Novartis is aware of employment scams ...

. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...

The Novartis Board of Directors is responsible for the direction, strategy, organization and administration of the company. The Board comprises 12 members with Giovanni Caforio as chair. Download the ...

Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 32 of the Condensed Interim Financial Report. Unless otherwise ...

Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the company's business operations. ECN members are chosen by the Board of Directors.

*Proportion of participants with complete response to FricTest® (TFS=0), TempTest® (CTT<4°C), or pulse-controlled ergometry test at week 12 (itch NRS score=0). About Rhapsido® Rhapsido (remibrutinib) ...

Novartis anuncia los resultados financieros del cuarto trimestre y del año completo 2024 de la compañía. Informe Integrado Novartis en la Sociedad 2024 Lee más sobre nuestro desempeño en relación con ...

studies were published in Nature Medicine. Following the CHMP’s recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months. About ...